Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction

Basit Öğe Kaydı
dc.authoridmert, kadir ugur/0000-0002-1331-5365
dc.authoridbasaran, ozcan/0000-0002-6384-6455
dc.contributor.authorOzlek, Bulent
dc.contributor.authorOzlek, Eda
dc.contributor.authorCelik, Oguzhan
dc.contributor.authorCil, Cem
dc.contributor.authorDogan, Volkan
dc.contributor.authorTekinalp, Mehmet
dc.contributor.authorAgus, Hicaz Zencirkiran
dc.date.accessioned2025-01-21T16:43:55Z
dc.date.available2025-01-21T16:43:55Z
dc.date.issued2018
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjective: Although almost half of chronic heart failure (HF) patients have mid-range (HFmrEF) and preserved left-ventricular ejection fraction (HFpEF), no studies have been carried out with these patients in our country. This study aims to determine the demographic characteristics and current status of the clinical background of HFmrEF and HFpEF patients in a multicenter trial. Methods: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction (APOLLON) trial will be an observational, multicenter, and noninterventional study conducted in Turkey. The study population will include 1065 patients from 12 sites in Turkey. All data will be collected at one point in time and the current clinical practice will be evaluated (ClinicalTrials.gov number NCT03026114). Results: We will enroll all consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had New York Heart Association class II, III, or IV HF, elevated brain natriuretic peptide levels within the last 30 days, and an left ventricular ejection fraction (LVEF) of at least 40%. Patients fulfilling the exclusion criteria will not be included in the study. Patients will be stratified into two categories according to LVEF: mid-range EF (HFmrEF, LVEF 40%-49%) and preserved EF (HFpEF, LVEF >= 50%). Regional quota sampling will be performed to ensure that the sample was representative of the Turkish population. Demographic, lifestyle, medical, and therapeutic data will be collected by this specific survey. Conclusion: The APOLLON trial will be the largest and most comprehensive study in Turkey evaluating HF patients with a LVEF >= 40% and will also be the first study to specifically analyze the recently designated HFmrEF category.
dc.identifier.doi10.14744/AnatolJCardiol.2018.95595
dc.identifier.endpage318
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue5
dc.identifier.pmid29724973
dc.identifier.startpage311
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2018.95595
dc.identifier.urihttps://hdl.handle.net/20.500.12587/25361
dc.identifier.volume19
dc.identifier.wosWOS:000435197000006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Soc Cardiology
dc.relation.ispartofAnatolian Journal of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectdemographic characteristics; heart failure with mid-range ejection fraction; heart failure with preserved ejection fraction
dc.titleRationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu